These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8766945)

  • 21. Transient elevation of serum growth hormone level during pituitary apoplexy in acromegaly.
    Taniyama M; Yonemaru M; Tanaka S; Maruyama T; Kataoka K; Matsuki S
    Arch Intern Med; 1986 May; 146(5):1001-3. PubMed ID: 3516099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case of acromegaly complicated with diabetic ketoacidosis, pituitary apoplexy, and lymphoma.
    Jiang HJ; Hung WW; Hsiao PJ
    Kaohsiung J Med Sci; 2013 Dec; 29(12):687-90. PubMed ID: 24296058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acromegaly and pregnancy: report of six new cases].
    Persechini ML; Gennero I; Grunenwald S; Vezzosi D; Bennet A; Caron P
    J Gynecol Obstet Biol Reprod (Paris); 2014 Nov; 43(9):704-12. PubMed ID: 24035359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
    Gradiser M; Matovinovic M; Vrkljan M
    Croat Med J; 2007 Feb; 48(1):87-91. PubMed ID: 17309144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of specific growth patterns and frequency of the empty sella phenomenon in growth hormone-secreting pituitary adenomas.
    Bier G; Hempel JM; Grimm F; Ernemann U; Bender B; Honegger J
    Eur J Radiol; 2018 Jul; 104():79-86. PubMed ID: 29857870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.
    Kinoshita Y; Tominaga A; Usui S; Arita K; Sakoguchi T; Sugiyama K; Kurisu K
    Neurosurg Rev; 2016 Apr; 39(2):313-8; discussion 318-9. PubMed ID: 26785642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly.
    Epaminonda P; Porretti S; Cappiello V; Beck-Peccoz P; Faglia G; Arosio M
    Clin Endocrinol (Oxf); 2001 Aug; 55(2):183-9. PubMed ID: 11531924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pituitary apoplexy in acromegaly during bromocriptine therapy.
    Yamaji T; Ishibashi M; Kosaka K; Fukushima T; Hori T; Manaka S; Sano K
    Acta Endocrinol (Copenh); 1981 Oct; 98(2):171-7. PubMed ID: 7293648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pituitary apoplexy after pneumoencefalogram].
    Perpétuo FO
    Arq Neuropsiquiatr; 1976 Sep; 34(3):298-301. PubMed ID: 962642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study.
    Bonert V; Carmichael J; Wu Z; Mirocha J; Perez DA; Clarke NJ; Reitz RE; McPhaul MJ; Mamelak A
    Pituitary; 2018 Feb; 21(1):65-75. PubMed ID: 29218459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pituitary apoplexy probably due to TRH and GnRH stimulation tests in a patient with acromegaly.
    Dökmetaş HS; Selçuklu A; Colak R; Unlühizarci K; Bayram F; Keleştimur F
    J Endocrinol Invest; 1999 Oct; 22(9):698-700. PubMed ID: 10595834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary apoplexy with spontaneous cure of acromegaly and its possible relation to Gd-DTPA-administration.
    Wichers M; Kristof RA; Springer W; Schramm J; Klingmüller D
    Acta Neurochir (Wien); 1997; 139(10):992-4. PubMed ID: 9401663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ectopic acromegaly due to a growth hormone-secreting neuroendocrine-differentiated tumor developed from ovarian mature cystic teratoma.
    Ozkaya M; Sayiner ZA; Kiran G; Gul K; Erkutlu I; Elboga U
    Wien Klin Wochenschr; 2015 Jun; 127(11-12):491-3. PubMed ID: 25869762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
    Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.